Sorriso Healthcares

Developer of disease-modifying antibodies designed for the treatment of inflammatory diseases, including Crohn's disease and ulcerative colitis. The company develops potent antibodies that can be delivered orally that deliver clinical impacts similar to that of injectable antibody therapeutics, enabling healthcare providers to relieve the treatment burden for patients who rely on drugs that can only be administered via injection.

New Enterprise Associates

🏥 Healthcare